TY - JOUR TI - BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era AU - Papageorgiou, S.G. AU - Kontos, C.K. AU - Foukas, P.G. AU - Panopoulou, E. AU - Vasilatou, D. AU - Rapti, S.-M. AU - Gkontopoulos, K. AU - Bazani, E. AU - Panayiotides, I.G. AU - Dimitriadis, G. AU - Scorilas, A. AU - Pappa, V. JO - Clinical Lymphoma Myeloma and Leukemia PY - 2016 VL - 57 TODO - 9 SP - 2199-2203 PB - Taylor and Francis Ltd. SN - null TODO - 10.3109/10428194.2015.1126588 TODO - BCL2L12 protein; common acute lymphoblastic leukemia antigen; cyclophosphamide; doxorubicin; interferon regulatory factor 4; Ki 67 antigen; messenger RNA; mitoxantrone; prednisone; protein bcl 2; protein bcl 6; protein p53; rituximab; tumor marker; unclassified drug; vincristine; antineoplastic agent; BCL2L12 protein, human; muscle protein; pharmacological biomarker; protein bcl 2; rituximab; tumor marker, apoptosis; B lymphocyte; B lymphocyte differentiation; cancer combination chemotherapy; cancer immunotherapy; cancer survival; chromosome 19q; disease free survival; follow up; gene dosage; gene locus; genetic heterogeneity; germinal center; human; immunohistochemistry; International Prognostic Index; large cell lymphoma; Letter; long term survival; outcome assessment; overall survival; priority journal; protein expression; recurrence free survival; survival rate; treatment response; diffuse large B cell lymphoma; gene expression regulation; genetics; HL-60 cell line; metabolism; mortality; prognosis; survival analysis; treatment outcome; upregulation, Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Lymphoma, Large B-Cell, Diffuse; Muscle Proteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Rituximab; Survival Analysis; Treatment Outcome; Up-Regulation TODO - null ER -